Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season

V. Fanos, A. Scarcella, M. Puddu, F. Gallini, F. Tuminelli, P. Bragetti, M. R. Gallina, L. Quartulli, N. Benincori, G. Citro, L. Dalla Via, G. Barera, U. Di Luzio Paparatti, R. Merolla, G. V. Romano, G. Guida, M. Silvestri, Giovanni A. Rossi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This prospective study evaluated the frequency and severity of respiratory symptoms during the second respiratory syncytial virus (RSV) season in an Italian cohort of preterm infants (≤35 weeks) who had received palivizumab prophylaxis in their first year of life (October 2004-April 2005) and who had not previously been hospitalized for RSV-induced lower respiratory tract infection (LRTI). Infants were evaluated at enrolment (May-September 2005), in October/November 2005 and in April 2006. The occurrence of any respiratory episode, the rate of hospitalization for respiratory-related LRTI, total length of stay in hospital, physician-documented recurrent wheezing (≥3 physician-documented episodes of wheezing) and use of airway medication/antibiotics were recorded during follow-up. All infants had prior palivizumab prophylaxis during their first RSV season. In the total evaluable population (n=260), 32.3% of infants experienced at least one respiratory episode, 3.8% required short hospitalization because of LRTI, 8.5% had physician-documented recurrent wheezing, and 48.8% required airway medications/antibiotics during follow-up. In this study the rate of airway morbidity, hospitalization and physician-documented recurrent wheezing during the second RSV season was low among preterm infants who had received prior palivizumab prophylaxis.

Original languageEnglish
Pages (from-to)302-310
Number of pages9
JournalJournal of Chemotherapy
Volume21
Issue number3
Publication statusPublished - Jun 2009

Fingerprint

Respiratory Syncytial Viruses
Respiratory Sounds
Premature Infants
Hospitalization
Respiratory Tract Infections
Physicians
Anti-Bacterial Agents
Respiratory Rate
Length of Stay
Prospective Studies
Morbidity
Palivizumab
Population

Keywords

  • Hospitalization
  • Palivizumab
  • Recurrent wheezing
  • Respiratory syncytial virus
  • RSV

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Cite this

Fanos, V., Scarcella, A., Puddu, M., Gallini, F., Tuminelli, F., Bragetti, P., ... Rossi, G. A. (2009). Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season. Journal of Chemotherapy, 21(3), 302-310.

Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season. / Fanos, V.; Scarcella, A.; Puddu, M.; Gallini, F.; Tuminelli, F.; Bragetti, P.; Gallina, M. R.; Quartulli, L.; Benincori, N.; Citro, G.; Dalla Via, L.; Barera, G.; Di Luzio Paparatti, U.; Merolla, R.; Romano, G. V.; Guida, G.; Silvestri, M.; Rossi, Giovanni A.

In: Journal of Chemotherapy, Vol. 21, No. 3, 06.2009, p. 302-310.

Research output: Contribution to journalArticle

Fanos, V, Scarcella, A, Puddu, M, Gallini, F, Tuminelli, F, Bragetti, P, Gallina, MR, Quartulli, L, Benincori, N, Citro, G, Dalla Via, L, Barera, G, Di Luzio Paparatti, U, Merolla, R, Romano, GV, Guida, G, Silvestri, M & Rossi, GA 2009, 'Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season', Journal of Chemotherapy, vol. 21, no. 3, pp. 302-310.
Fanos, V. ; Scarcella, A. ; Puddu, M. ; Gallini, F. ; Tuminelli, F. ; Bragetti, P. ; Gallina, M. R. ; Quartulli, L. ; Benincori, N. ; Citro, G. ; Dalla Via, L. ; Barera, G. ; Di Luzio Paparatti, U. ; Merolla, R. ; Romano, G. V. ; Guida, G. ; Silvestri, M. ; Rossi, Giovanni A. / Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season. In: Journal of Chemotherapy. 2009 ; Vol. 21, No. 3. pp. 302-310.
@article{979c5ef93bef403192692ad000f932bb,
title = "Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season",
abstract = "This prospective study evaluated the frequency and severity of respiratory symptoms during the second respiratory syncytial virus (RSV) season in an Italian cohort of preterm infants (≤35 weeks) who had received palivizumab prophylaxis in their first year of life (October 2004-April 2005) and who had not previously been hospitalized for RSV-induced lower respiratory tract infection (LRTI). Infants were evaluated at enrolment (May-September 2005), in October/November 2005 and in April 2006. The occurrence of any respiratory episode, the rate of hospitalization for respiratory-related LRTI, total length of stay in hospital, physician-documented recurrent wheezing (≥3 physician-documented episodes of wheezing) and use of airway medication/antibiotics were recorded during follow-up. All infants had prior palivizumab prophylaxis during their first RSV season. In the total evaluable population (n=260), 32.3{\%} of infants experienced at least one respiratory episode, 3.8{\%} required short hospitalization because of LRTI, 8.5{\%} had physician-documented recurrent wheezing, and 48.8{\%} required airway medications/antibiotics during follow-up. In this study the rate of airway morbidity, hospitalization and physician-documented recurrent wheezing during the second RSV season was low among preterm infants who had received prior palivizumab prophylaxis.",
keywords = "Hospitalization, Palivizumab, Recurrent wheezing, Respiratory syncytial virus, RSV",
author = "V. Fanos and A. Scarcella and M. Puddu and F. Gallini and F. Tuminelli and P. Bragetti and Gallina, {M. R.} and L. Quartulli and N. Benincori and G. Citro and {Dalla Via}, L. and G. Barera and {Di Luzio Paparatti}, U. and R. Merolla and Romano, {G. V.} and G. Guida and M. Silvestri and Rossi, {Giovanni A.}",
year = "2009",
month = "6",
language = "English",
volume = "21",
pages = "302--310",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season

AU - Fanos, V.

AU - Scarcella, A.

AU - Puddu, M.

AU - Gallini, F.

AU - Tuminelli, F.

AU - Bragetti, P.

AU - Gallina, M. R.

AU - Quartulli, L.

AU - Benincori, N.

AU - Citro, G.

AU - Dalla Via, L.

AU - Barera, G.

AU - Di Luzio Paparatti, U.

AU - Merolla, R.

AU - Romano, G. V.

AU - Guida, G.

AU - Silvestri, M.

AU - Rossi, Giovanni A.

PY - 2009/6

Y1 - 2009/6

N2 - This prospective study evaluated the frequency and severity of respiratory symptoms during the second respiratory syncytial virus (RSV) season in an Italian cohort of preterm infants (≤35 weeks) who had received palivizumab prophylaxis in their first year of life (October 2004-April 2005) and who had not previously been hospitalized for RSV-induced lower respiratory tract infection (LRTI). Infants were evaluated at enrolment (May-September 2005), in October/November 2005 and in April 2006. The occurrence of any respiratory episode, the rate of hospitalization for respiratory-related LRTI, total length of stay in hospital, physician-documented recurrent wheezing (≥3 physician-documented episodes of wheezing) and use of airway medication/antibiotics were recorded during follow-up. All infants had prior palivizumab prophylaxis during their first RSV season. In the total evaluable population (n=260), 32.3% of infants experienced at least one respiratory episode, 3.8% required short hospitalization because of LRTI, 8.5% had physician-documented recurrent wheezing, and 48.8% required airway medications/antibiotics during follow-up. In this study the rate of airway morbidity, hospitalization and physician-documented recurrent wheezing during the second RSV season was low among preterm infants who had received prior palivizumab prophylaxis.

AB - This prospective study evaluated the frequency and severity of respiratory symptoms during the second respiratory syncytial virus (RSV) season in an Italian cohort of preterm infants (≤35 weeks) who had received palivizumab prophylaxis in their first year of life (October 2004-April 2005) and who had not previously been hospitalized for RSV-induced lower respiratory tract infection (LRTI). Infants were evaluated at enrolment (May-September 2005), in October/November 2005 and in April 2006. The occurrence of any respiratory episode, the rate of hospitalization for respiratory-related LRTI, total length of stay in hospital, physician-documented recurrent wheezing (≥3 physician-documented episodes of wheezing) and use of airway medication/antibiotics were recorded during follow-up. All infants had prior palivizumab prophylaxis during their first RSV season. In the total evaluable population (n=260), 32.3% of infants experienced at least one respiratory episode, 3.8% required short hospitalization because of LRTI, 8.5% had physician-documented recurrent wheezing, and 48.8% required airway medications/antibiotics during follow-up. In this study the rate of airway morbidity, hospitalization and physician-documented recurrent wheezing during the second RSV season was low among preterm infants who had received prior palivizumab prophylaxis.

KW - Hospitalization

KW - Palivizumab

KW - Recurrent wheezing

KW - Respiratory syncytial virus

KW - RSV

UR - http://www.scopus.com/inward/record.url?scp=68349091350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349091350&partnerID=8YFLogxK

M3 - Article

C2 - 19567351

AN - SCOPUS:68349091350

VL - 21

SP - 302

EP - 310

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -